Transcenta, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today results reported for the first time from a Phase 1 - study (NCT04272944) of MSB2311, an investigational PDL1 targeting antibody with pH dependent and tumor recycling property developed by Transcenta's subsidiary Mabspace Biosciences (Suzhou) Co., Ltd, in the treatment of Chinese patients with pre-treated advanced solid tumors and select hematological malignancies.

Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing, today announced that its subsidiary Mabspace Biosciences (Suzhou) Co., Limited has received clearance of its IND from FDA for its novel humanized Claudin 18.2 (CLDN18.2) monoclonal antibody (internal project number TST001). It is developed jointly by Mabspace Biosciences and HJB, another Transcenta’s subsidiary focusing on CMC and manufacturing.

Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing, today announced that its subsidiary Mabspace Biosciences (Suzhou) Co., Limited has received the clearance from the National Medical Products Administration (NMPA) to initiate Phase I clinical trials in China for its Claudin 18.2 (CLDN18.2) humanized monoclonal antibody, TST001. TST001 was developed jointly by scientists from Mabspace and HJB, Transcenta’s subsidiary focusing on CMC and manufacturing.

Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing, today announced an expansion of their joint innovation partnership with 908 Devices, a pioneer of analytical devices for chemical and biomolecular analysis.

Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D, regulatory affairs and manufacturing, today announced it has achieved a major milestone in its continuous perfusion cell culture platform by achieving volumetric productivities of > 4 g/L per day for multiple cell lines expressing monoclonal antibodies.

Transcenta announces today that an investigational new drug (IND) application of its humanized Claudin 18.2 (CLDN18.2) monoclonal antibody (also known as TST001 internally) for the treatment of solid tumors has been accepted by the CDE of NMPA of China.